Bohlender J, Ménard J, Wagner J, Luft F C, Ganten D
Max-Delbrück-Centrum für Molekulare Medizin, Berlin-Buch, Allemagne.
Arch Mal Coeur Vaiss. 1996 Aug;89(8):1009-11.
The effective development of human renin inhibitors meets its major obstacle in the absence of a suitable experimental rodent model and the species-specificity of human renin, exclusively cleaving its natural substrate human angiotensinogen. We have reconstructed the human renin-angiotensin system in transgenic rats over expressing the human angiotensinogen gene TGR (hAOGEN) 1623 by chronically injecting i.v. human recombinant renin. We have first established new in vitro enzyme kinetic techniques to measure the various components of the chimeric renin-angiotensin system and distinguished the two human and rat-specific pathways of generating angiotensin I by the human specific renin inhibitor Ro 42-5892 (Hoffmann-La Roche). Male heterozygous TGR had plasma levels of rat angiotensinogen of 1.2 +/- 0.2 mg Ang l/ml while the plasma levels of the transgene were 141 +/- 98 mg Ang l/ml (n = 41; not normally distributed). Transgene expression was found in the liver kidney, aorta, heart and adrenals. Four rats were infused i.v. with human recombinant renin at 50 ng/h over 9 days which chronically increased their blood pressure to > 200 mmHg while total plasma renin activity increased by a factor of 300. Rat renin disappeared form the plasma. This new model of experimental human renin-induced hypertension in rats will facilitate the screening and characterization of human renin inhibitors.
人类肾素抑制剂的有效研发面临着一个主要障碍,即缺乏合适的实验啮齿动物模型以及人类肾素的物种特异性,人类肾素仅能裂解其天然底物人血管紧张素原。我们通过长期静脉注射人重组肾素,在过量表达人血管紧张素原基因TGR(hAOGEN)1623的转基因大鼠中重建了人类肾素 - 血管紧张素系统。我们首先建立了新的体外酶动力学技术来测量嵌合肾素 - 血管紧张素系统的各种成分,并通过人特异性肾素抑制剂Ro 42 - 5892(霍夫曼 - 罗氏公司)区分了生成血管紧张素I的两条人类和大鼠特异性途径。雄性杂合TGR大鼠的大鼠血管紧张素原血浆水平为1.2±0.2 mg Ang I/ml,而转基因的血浆水平为141±98 mg Ang I/ml(n = 41;非正态分布)。在肝脏、肾脏、主动脉、心脏和肾上腺中发现了转基因表达。4只大鼠在9天内以50 ng/h的速度静脉输注人重组肾素,这使其血压长期升高至>200 mmHg,而血浆总肾素活性增加了300倍。大鼠肾素从血浆中消失。这种新的大鼠实验性人类肾素诱导高血压模型将有助于人类肾素抑制剂的筛选和特性研究。